A preprint examine posted late final week on the server medRxiv reveals that the present Moderna COVID-19 vaccine is 53% efficient towards COVID-19–associated hospitalization and 39% protecting towards medically attended COVID-19 over a median follow-up interval of 57 days.
The examine, which has not but been peer-reviewed, evaluated the effectiveness of Moderna’s up to date vaccine concentrating on the KP.2 variant at stopping hospitalizations and medically attended COVID-19 sickness. Outcomes amongst recipients of the vaccine have been in comparison with individuals who didn’t obtain any 2024-25 COVID vaccine.
The retrospective matched cohort examine used digital well being information to find out vaccinations from August 23, 2024, by December 24, 2024, and with follow-up by December 31, 2024. Total, 465,073 KP.2 vaccine recipients have been matched 1:1 to unexposed adults.
70% had underlying medical circumstances
The common age of contributors was 63 years, with greater than half being 65 years or older. Seventy p.c of individuals within the examine had an underlying medical situation that made them excessive threat for extreme COVID-19 outcomes.
The most typical underlying medical circumstances have been weight problems (uncovered, 25.3%; unexposed, 26.5%), diabetes mellitus (21.7% and 23.5%, respectively), and coronary heart circumstances (17.9% and 19.7%, respectively).
“Most sufferers (73%) within the examine inhabitants had documentation of a earlier vaccination for COVID-19,” the authors mentioned.
Decrease safety in these with underlying circumstances
Vaccine effectiveness (VE) was 52.8% (95% confidence interval [CI]34.8% to 65.8%) towards COVID-19–associated hospitalization, and 39.4% (95% CI; 35.0% to 43.5%) towards medically attended COVID-19 over a median follow-up of 57 days.
Adjusted VE towards COVID-19–associated hospitalization was 53.1% for adults 50 years outdated or older, 53.2% amongst adults 65 years outdated or older, and 46.5% amongst adults with no less than one underlying medical situation. Adjusted VE towards medically attended COVID-19 was 41.2% for adults ages 50 years outdated and older, 46.7% amongst these 65 years outdated or older, and 40.4% amongst adults with no less than one underlying medical situation.
Most people within the examine (over 70%) beforehand acquired a 2023-2024 mRNA-1273 [Moderna] vaccine concentrating on the XBB.1.5 variant.
“Most people within the examine (over 70%) beforehand acquired a 2023-2024 mRNA-1273 [Moderna] vaccine concentrating on the XBB.1.5 variant. Thus, the outcomes of this examine needs to be interpreted within the context of the incremental safety towards hospitalization supplied by probably the most up to date COVID-19 towards the circulating variants in a real-world setting no matter publicity and/or vaccination historical past,” the authors mentioned.
